SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001628280-22-006406
Filing Date
2022-03-16
Accepted
2022-03-16 17:09:13
Documents
5
Period of Report
2022-04-28

Document Format Files

Seq Description Document Type Size
1 DEF 14A a2022proxystatement.htm DEF 14A 517058
2 GRAPHIC ajbackgroundpicture.jpg GRAPHIC 10605
3 GRAPHIC cumberlandlogoa02a01.jpg GRAPHIC 12534
4 GRAPHIC cumberlandpharmalogoa01.jpg GRAPHIC 37721
5 GRAPHIC xa01.jpg GRAPHIC 2405
  Complete submission text file 0001628280-22-006406.txt   605791
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-33637 | Film No.: 22745710
SIC: 2834 Pharmaceutical Preparations